RxSight, Inc. (RXST)
| Market Cap | 190.36M -44.5% |
| Revenue (ttm) | 121.83M -14.3% |
| Net Income | -53.36M |
| EPS | -1.29 |
| Shares Out | 41.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 948,254 |
| Open | 4.550 |
| Previous Close | 4.540 |
| Day's Range | 4.360 - 4.600 |
| 52-Week Range | 4.110 - 13.220 |
| Beta | 1.19 |
| Analysts | Hold |
| Price Target | 7.57 (+66.72%) |
| Earnings Date | Nov 3, 2026 |
About RXST
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be... [Read more]
Financial Performance
In 2025, RxSight's revenue was $134.48 million, a decrease of -3.89% compared to the previous year's $139.93 million. Losses were -$38.94 million, 41.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for RXST stock is "Hold." The 12-month stock price target is $7.57, which is an increase of 66.72% from the latest price.
News
RxSight price target lowered to $8 from $10 at Piper Sandler
Piper Sandler lowered the firm’s price target on RxSight (RXST) to $8 from $10 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 top-line…
RxSight price target lowered to $5 from $7 at Stifel
Stifel analyst Thomas Stephan lowered the firm’s price target on RxSight (RXST) to $5 from $7 and keeps a Hold rating on the shares.
RxSight price target lowered to $6 from $9 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on RxSight (RXST) to $6 from $9 and keeps an Equal Weight rating on the shares. The firm notes the…
RxSight reports Q3 EPS (21c), consensus (29c)
Reports Q3 revenue $24.59M, consensus $27.14M. “Since I joined last quarter, the team has moved quickly and accomplished a great deal in a short period of time,” said Aziz Mottiwala,…
RxSight says nearly doubling sales force, completed organizational restructuring
16:41 EST RxSight (RXST) says nearly doubling sales force, completed organizational restructuring
RxSight Earnings Call Transcript: Q3 2026
Q3 revenue fell 19% YoY as LAL procedures declined amid competitive pressure, seasonality, and commercial restructuring. Priorities are rebuilding U.S. utilization, advancing the lens pipeline, and executing the Alcon collaboration, with lower OpEx expected in 2027.
RxSight Earnings release: Q3 2026
RxSight released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
RxSight Quarterly report: Q3 2026
RxSight has published its Q3 2026 quarterly earnings report on November 3, 2026.
RxSight, Inc. Reports Third Quarter 2026 Results
ALISO VIEJO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended September 30, 2026.
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 sh...
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tue...
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice Pre...
K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
K2 Vision has performed 5,000+ Light Adjustable Lens procedures and is recognized by RxSight as the highest-volume LAL practice in the world. Learn more.
RxSight price target lowered to $5.75 from $6.50 at Jefferies
Jefferies lowered the firm’s price target on RxSight (RXST) to $5.75 from $6.50 and keeps a Hold rating on the shares. The ophthalmology sector has been under pressure over the…
RxSight price target lowered to $5.50 from $6.50 at BofA
BofA lowered the firm’s price target on RxSight (RXST) to $5.50 from $6.50 and keeps an Underperform rating on the shares. Due diligence with doctors suggests structural barriers and competitive…
RxSight Transcript: Wells Fargo 21st Annual Healthcare Conference
Management is focused on revitalizing U.S. growth through deeper user engagement, education, and operational discipline, while leveraging the Alcon partnership and pipeline development for long-term market transformation. The business aims to return to growth by 2027, maintaining strong margins and capital efficiency.
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, S...
RxSight price target lowered to $7 from $8 at Stifel
Stifel lowered the firm’s price target on RxSight (RXST) to $7 from $8 and keeps a Hold rating on the shares. The firm updated its model following the Q2 10-Q…
RxSight price target raised to $6.30 from $5.50 at UBS
UBS raised the firm’s price target on RxSight (RXST) to $6.30 from $5.50 and keeps a Neutral rating on the shares.
RxSight says withdrawing guidance, will resume formal guidance in 2027
In connection with the leadership transition, RxSight (RXST) announced Wednesday that it withdrew 2026 guidance and will resume formal guidance in early 2027.
RxSight reports Q2 adjusted EPS (11c), consensus (19c)
Reports Q2 revenue $33.74M, consensus $32.55M. “It is a privilege to join RxSight (RXST) and to work alongside the talented team that pioneered an entirely new category in cataract surgery…
RxSight Earnings Call Transcript: Q2 2026
Q2 revenue reached $33.7M, with core product sales down 19% year-over-year amid competitive and market headwinds. The Alcon collaboration brought $6.5M in Q2 and is expected to contribute $30–$40M in 2026. Full-year guidance was withdrawn pending a strategic business assessment.
RxSight Earnings release: Q2 2026
RxSight released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
RxSight Quarterly report: Q2 2026
RxSight has published its Q2 2026 quarterly earnings report on August 5, 2026.
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial o...